BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 22521076)

  • 1. Anterior gradient 2 profiling in Barrett columnar epithelia and adenocarcinoma.
    Pizzi M; Fassan M; Realdon S; Balistreri M; Battaglia G; Giacometti C; Zaninotto G; Zagonel V; De Boni M; Rugge M
    Hum Pathol; 2012 Nov; 43(11):1839-44. PubMed ID: 22521076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus.
    Lord RV; Park JM; Wickramasinghe K; DeMeester SR; Oberg S; Salonga D; Singer J; Peters JH; Danenberg KD; Demeester TR; Danenberg PV
    J Thorac Cardiovasc Surg; 2003 Feb; 125(2):246-53. PubMed ID: 12579092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.
    Glickman JN; Yang A; Shahsafaei A; McKeon F; Odze RD
    Hum Pathol; 2001 Nov; 32(11):1157-65. PubMed ID: 11727253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions.
    Montgomery E; Mamelak AJ; Gibson M; Maitra A; Sheikh S; Amr SS; Yang S; Brock M; Forastiere A; Zhang S; Murphy KM; Berg KD
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):24-30. PubMed ID: 16540726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis.
    Fassan M; Pizzi M; Battaglia G; Giacomelli L; Parente P; Bocus P; Ancona E; Rugge M
    J Clin Pathol; 2010 Aug; 63(8):692-6. PubMed ID: 20702469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
    Fassan M; Mastracci L; Grillo F; Zagonel V; Bruno S; Battaglia G; Pitto F; Nitti D; Celiento T; Zaninotto G; Fiocca R; Rugge M
    Histopathology; 2012 Nov; 61(5):769-76. PubMed ID: 22882541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma.
    Dvorak K; Watts GS; Ramsey L; Holubec H; Payne CM; Bernstein C; Jenkins GJ; Sampliner RE; Prasad A; Garewal HS; Bernstein H
    Am J Gastroenterol; 2009 Feb; 104(2):302-9. PubMed ID: 19174784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus.
    Makita K; Kitazawa R; Semba S; Fujiishi K; Nakagawa M; Haraguchi R; Kitazawa S
    World J Gastroenterol; 2013 Jan; 19(4):536-41. PubMed ID: 23382633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of acidic fibroblast growth factor in Barrett's esophagus and associated esophageal adenocarcinoma.
    Soslow RA; Ying L; Altorki NK
    J Thorac Cardiovasc Surg; 1997 Nov; 114(5):838-43. PubMed ID: 9375615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett's Esophagus and Adenocarcinoma.
    Fisher OM; Levert-Mignon AJ; Lord SJ; Botelho NK; Freeman AK; Thomas ML; Falkenback D; Wettstein A; Whiteman DC; Bobryshev YV; Lord RV
    Ann Surg Oncol; 2015 Jul; 22(7):2431-8. PubMed ID: 25348778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
    Feith M; Stein HJ; Mueller J; Siewert JR
    Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of C1q complement component in Barrett's esophagus and esophageal adenocarcinoma.
    Bobryshev YV; Lu J; Lord RV
    J Gastrointest Surg; 2010 Aug; 14(8):1207-13. PubMed ID: 20496011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative proteomics analysis of Barrett metaplasia and esophageal adenocarcinoma using two-dimensional liquid mass mapping.
    Zhao J; Chang AC; Li C; Shedden KA; Thomas DG; Misek DE; Manoharan AP; Giordano TJ; Beer DG; Lubman DM
    Mol Cell Proteomics; 2007 Jun; 6(6):987-99. PubMed ID: 16829691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.
    Lord RV; Salonga D; Danenberg KD; Peters JH; DeMeester TR; Park JM; Johansson J; Skinner KA; Chandrasoma P; DeMeester SR; Bremner CG; Tsai PI; Danenberg PV
    J Gastrointest Surg; 2000; 4(2):135-42. PubMed ID: 10675236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microsatellite alterations in phenotypically normal esophageal squamous epithelium and metaplasia-dysplasia-adenocarcinoma sequence.
    Cai JC; Liu D; Liu KH; Zhang HP; Zhong S; Xia NS
    World J Gastroenterol; 2008 Jul; 14(25):4070-6. PubMed ID: 18609693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
    Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
    Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
    Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
    Soslow RA; Remotti H; Baergen RN; Altorki NK
    Mod Pathol; 1999 Mar; 12(3):239-50. PubMed ID: 10102608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target.
    Hansel DE; Dhara S; Huang RC; Ashfaq R; Deasel M; Shimada Y; Bernstein HS; Harmon J; Brock M; Forastiere A; Washington MK; Maitra A; Montgomery E
    Am J Surg Pathol; 2005 Mar; 29(3):390-9. PubMed ID: 15725809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.